

# Albert C M Ong

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5847025/publications.pdf>

Version: 2024-02-01

167  
papers

6,824  
citations

57631

44  
h-index

69108

77  
g-index

260  
all docs

260  
docs citations

260  
times ranked

6229  
citing authors

#	ARTICLE	IF	CITATIONS
1	Polycystin, the polycystic kidney disease 1 protein, is expressed by epithelial cells in fetal, adult, and polycystic kidney.. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 1524-1528.	3.3	239
2	Autosomal dominant polycystic kidney disease: the changing face of clinical management. Lancet, The, 2015, 385, 1993-2002.	6.3	227
3	Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice. Nephrology Dialysis Transplantation, 2016, 31, 337-348.	0.4	206
4	Molecular pathogenesis of ADPKD: The polycystin complex gets complex. Kidney International, 2005, 67, 1234-1247.	2.6	202
5	Association of mutation position in polycystic kidney disease 1 (PKD1) gene and development of a vascular phenotype. Lancet, The, 2003, 361, 2196-2201.	6.3	198
6	Fabrication and Luminescence of Monolayered Boron Nitride Quantum Dots. Small, 2014, 10, 60-65.	5.2	196
7	Rare inherited kidney diseases: challenges, opportunities, and perspectives. Lancet, The, 2014, 383, 1844-1859.	6.3	194
8	Fabrication of Luminescent Monolayered Tungsten Dichalcogenides Quantum Dots with Giant Spin-Valley Coupling. ACS Nano, 2013, 7, 8214-8223.	7.3	181
9	Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival--an analysis of data from the ERA-EDTA Registry. Nephrology Dialysis Transplantation, 2014, 29, iv15-iv25.	0.4	180
10	Identification, Characterization, and Localization of a Novel Kidney Polycystin-1-Polycystin-2 Complex. Journal of Biological Chemistry, 2002, 277, 20763-20773.	1.6	178
11	Coordinate Expression of the Autosomal Dominant Polycystic Kidney Disease Proteins, Polycystin-2 And Polycystin-1, in Normal and Cystic Tissue. American Journal of Pathology, 1999, 154, 1721-1729.	1.9	174
12	Structural and molecular basis of the assembly of the TRPP2/PKD1 complex. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 11558-11563.	3.3	163
13	A polycystin-centric view of cyst formation and disease: the polycystins revisited. Kidney International, 2015, 88, 699-710.	2.6	140
14	Polycystic kidney disease--the ciliary connection. Lancet, The, 2003, 361, 774-776.	6.3	130
15	Functional characterization of GATA3 mutations causing the hypoparathyroidism-deafness-renal (HDR) dysplasia syndrome: insight into mechanisms of DNA binding by the GATA3 transcription factor. Human Molecular Genetics, 2006, 16, 265-275.	1.4	129
16	Involvement of Hypoxia-Inducible Transcription Factors in Polycystic Kidney Disease. American Journal of Pathology, 2007, 170, 830-842.	1.9	118
17	Loss of glomerular function and tubulointerstitial fibrosis: Cause or effect?. Kidney International, 1994, 45, 345-351.	2.6	111
18	The pathogenesis of the ovarian hyperstimulation syndrome (OHS): a possible role for ovarian renin. Clinical Endocrinology, 1991, 34, 43-49.	1.2	101

#	ARTICLE	IF	CITATIONS
19	Identification of Mutations in the Duplicated Region of the Polycystic Kidney Disease 1 Gene (PKD1) by a Novel Approach. <i>American Journal of Human Genetics</i> , 1997, 60, 1399-1410.	2.6	100
20	An endothelin-1 mediated autocrine growth loop involved in human renal tubular regeneration. <i>Kidney International</i> , 1995, 48, 390-401.	2.6	99
21	Mechanisms of tubulo-interstitial injury in progressive renal diseases. <i>European Journal of Clinical Investigation</i> , 1993, 23, 259-265.	1.7	94
22	A stable, nonsense mutation associated with a case of infantile onset polycystic kidney disease 1 (PKD1). <i>Human Molecular Genetics</i> , 1996, 5, 539-542.	1.4	94
23	Analysis of data from the ERA-EDTA Registry indicates that conventional treatments for chronic kidney disease do not reduce the need for renal replacement therapy in autosomal dominant polycystic kidney disease. <i>Kidney International</i> , 2014, 86, 1244-1252.	2.6	91
24	Magnetic resonance imaging biomarkers for chronic kidney disease: a position paper from the European Cooperation in Science and Technology Action PARENCHIMA. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, ii4-ii14.	0.4	91
25	Polycystic Kidney Disease Is a Risk Factor for New-Onset Diabetes After Transplantation. <i>Transplantation</i> , 2007, 83, 36-40.	0.5	90
26	Polycystin-1 expression in PKD1, early-onset PKD1, and TSC2/PKD1 cystic tissue. <i>Kidney International</i> , 1999, 56, 1324-1333.	2.6	87
27	Identification of an N-terminal glycogen synthase kinase 3 phosphorylation site which regulates the functional localization of polycystin-2 in vivo and in vitro. <i>Human Molecular Genetics</i> , 2006, 15, 1465-1473.	1.4	83
28	Tubular-Derived Growth Factors and Cytokines in the Pathogenesis of Tubulointerstitial Fibrosis: Implications for Human Renal Disease Progression. <i>American Journal of Kidney Diseases</i> , 1994, 23, 205-209.	2.1	81
29	Haploinsufficiency of Pkd2 is associated with increased tubular cell proliferation and interstitial fibrosis in two murine Pkd2 models. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 2078-2084.	0.4	78
30	Functional Analysis of PKD1 Transgenic Lines Reveals a Direct Role for Polycystin-1 in Mediating Cell-Cell Adhesion. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, 1804-1815.	3.0	77
31	Hyperproliferation of PKD1 cystic cells is induced by insulin-like growth factor-1 activation of the Ras/Raf signalling system. <i>Kidney International</i> , 2007, 72, 157-165.	2.6	74
32	Candidate 56 and 58 kDa protein(s) responsible for mediating the renal defects in oncogenic hypophosphatemic osteomalacia. <i>Bone</i> , 1996, 18, 159-169.	1.4	72
33	A polycystin-2 (TRPP2) dimerization domain essential for the function of heteromeric polycystin complexes. <i>EMBO Journal</i> , 2010, 29, 1176-1191.	3.5	70
34	Imaging of Kidney Cysts and Cystic Kidney Diseases in Children: An International Working Group Consensus Statement. <i>Radiology</i> , 2019, 290, 769-782.	3.6	69
35	Autosomal Dominant Polycystic Kidney Disease: Recent Advances in Pathogenesis and Treatment. <i>Nephron Physiology</i> , 2008, 108, p1-p7.	1.5	63
36	Monoallelic IFT140 pathogenic variants are an important cause of the autosomal dominant polycystic kidney-spectrum phenotype. <i>American Journal of Human Genetics</i> , 2022, 109, 136-156.	2.6	62

#	ARTICLE	IF	CITATIONS
37	Mechanism-Based Therapeutics for Autosomal Dominant Polycystic Kidney Disease: Recent Progress and Future Prospects. <i>Nephron Clinical Practice</i> , 2012, 120, c25-c35.	2.3	61
38	Small-molecule allosteric activators of PDE4 long form cyclic AMP phosphodiesterases. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 13320-13329.	3.3	54
39	Identification and Functional Characterization of an N-terminal Oligomerization Domain for Polycystin-2. <i>Journal of Biological Chemistry</i> , 2008, 283, 28471-28479.	1.6	50
40	Human high density lipoproteins stimulate endothelin-1 release by cultured human renal proximal tubular cells. <i>Kidney International</i> , 1994, 46, 1315-1321.	2.6	49
41	Homophilic and heterophilic polycystin 1 interactions regulate E-cadherin recruitment and junction assembly in MDCK cells. <i>Journal of Cell Science</i> , 2009, 122, 1410-1417.	1.2	48
42	Molecular basis of renal cyst formation—“one hit or two?”. <i>Lancet, The</i> , 1997, 349, 1039-1040.	6.3	47
43	Hyperphosphorylation of polycystin-2 at a critical residue in disease reveals an essential role for polycystin-1-regulated dephosphorylation. <i>Human Molecular Genetics</i> , 2013, 22, 1924-1939.	1.4	47
44	How simple are 'simple renal cysts'?. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, iv106-iv112.	0.4	44
45	Detection and characterization of mosaicism in autosomal dominant polycystic kidney disease. <i>Kidney International</i> , 2020, 97, 370-382.	2.6	44
46	An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 825-839.	0.4	44
47	STAT5 drives abnormal proliferation in autosomal dominant polycystic kidney disease. <i>Kidney International</i> , 2017, 91, 575-586.	2.6	41
48	Effect of cyclosporin A on endothelin synthesis by cultured human renal cortical epithelial cells. <i>Nephrology Dialysis Transplantation</i> , 1993, 8, 748-753.	0.4	40
49	Aberrant Polycystin-1 Expression Results in Modification of Activator Protein-1 Activity, whereas Wnt Signaling Remains Unaffected. <i>Journal of Biological Chemistry</i> , 2004, 279, 27472-27481.	1.6	40
50	Endothelin B Receptor Blockade Accelerates Disease Progression in a Murine Model of Autosomal Dominant Polycystic Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2007, 18, 560-569.	3.0	40
51	Global microRNA profiling in human urinary exosomes reveals novel disease biomarkers and cellular pathways for autosomal dominant polycystic kidney disease. <i>Kidney International</i> , 2020, 98, 420-435.	2.6	40
52	Metabolic abnormalities in autosomal dominant polycystic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 197-203.	0.4	38
53	Increased psychosocial risk, depression and reduced quality of life living with autosomal dominant polycystic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1130-1140.	0.4	38
54	Activation of TRPP2 through mDia1-dependent voltage gating. <i>EMBO Journal</i> , 2008, 27, 1345-1356.	3.5	37

#	ARTICLE	IF	CITATIONS
55	New treatments for autosomal dominant polycystic kidney disease. <i>British Journal of Clinical Pharmacology</i> , 2013, 76, n/a-n/a.	1.1	37
56	Protein Kinase C-mediated Phosphorylation of Polycystin-2 (TRPP2) Is Essential for Its Effects on Cell Growth and Calcium Channel Activity. <i>Molecular Biology of the Cell</i> , 2010, 21, 3853-3865.	0.9	36
57	Tubular lipidosis: Epiphenomenon or pathogenetic lesion in human renal disease?. <i>Kidney International</i> , 1994, 45, 753-762.	2.6	34
58	The natural history of autosomal dominant polycystic kidney disease: 30-year experience from a single centre. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2013, 106, 639-646.	0.2	34
59	A model to predict disease progression in patients with autosomal dominant polycystic kidney disease (ADPKD): the ADPKD Outcomes Model. <i>BMC Nephrology</i> , 2018, 19, 37.	0.8	34
60	Regional Variations in Endothelin-1 and its Receptor Subtypes in Human Coronary Vasculature: Pathophysiological Implications in Coronary Disease. <i>Endothelium: Journal of Endothelial Cell Research</i> , 1998, 6, 61-70.	1.7	32
61	Angiotensin-1 regulates microvascular reactivity and protects the microcirculation during acute endothelial dysfunction: Role of eNOS and VE-cadherin. <i>Pharmacological Research</i> , 2014, 80, 43-51.	3.1	31
62	Biallelic inheritance of hypomorphic PKD1 variants is highly prevalent in very early onset polycystic kidney disease. <i>Genetics in Medicine</i> , 2021, 23, 689-697.	1.1	31
63	Polycystin Expression in the Kidney and Other Tissues: Complexity, Consensus and Controversy. <i>Nephron Experimental Nephrology</i> , 2000, 8, 208-214.	2.4	30
64	Cosegregation of Focal Segmental Glomerulosclerosis in a Family with Familial Partial Lipodystrophy due to a Mutation in <i>LMNA</i> . <i>Nephron Clinical Practice</i> , 2013, 124, 31-37.	2.3	29
65	The Polycystin-1, Lipoxygenase, and $\beta$ -Toxin Domain Regulates Polycystin-1 Trafficking. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 1159-1173.	3.0	29
66	Cystic kidney diseases: many ways to form a cyst. <i>Pediatric Nephrology</i> , 2013, 28, 33-49.	0.9	28
67	European ADPKD Forum multidisciplinary position statement on autosomal dominant polycystic kidney disease care. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 563-573.	0.4	28
68	Expression and Cellular Localisation of Renal Endothelin-1 and Endothelin Receptor Subtypes in Autosomal-Dominant Polycystic Kidney Disease. <i>Nephron Experimental Nephrology</i> , 2003, 93, e80-e86.	2.4	27
69	Targeting new cellular disease pathways in autosomal dominant polycystic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 1310-1316.	0.4	27
70	An international cohort study of autosomal dominant tubulointerstitial kidney disease due to mutations identifies distinct clinical subtypes. <i>Kidney International</i> , 2020, 98, 1589-1604.	2.6	27
71	Long-acting somatostatin analogue treatments in autosomal dominant polycystic kidney disease and polycystic liver disease: a systematic review and meta-analysis. <i>BMJ Open</i> , 2020, 10, e032620.	0.8	27
72	Detection of Proximal Tubular Motile Cilia in a Patient With Renal Sarcoidosis Associated With Hypercalcemia. <i>American Journal of Kidney Diseases</i> , 2005, 45, 1096-1099.	2.1	26

#	ARTICLE	IF	CITATIONS
73	Parallel microarray profiling identifies ErbB4 as a determinant of cyst growth in ADPKD and a prognostic biomarker for disease progression. <i>American Journal of Physiology - Renal Physiology</i> , 2017, 312, F577-F588.	1.3	26
74	Pkd2 mesenteric vessels exhibit a primary defect in endothelium-dependent vasodilatation restored by rosiglitazone. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2013, 304, H33-H41.	1.5	25
75	The positive effect of selective prostaglandin E2 receptor EP2 and EP4 blockade on cystogenesis in vitro is counteracted by increased kidney inflammation in vivo. <i>Kidney International</i> , 2020, 98, 404-419.	2.6	25
76	Coronavirus-associated kidney outcomes in COVID-19, SARS, and MERS: a meta-analysis and systematic review. <i>Renal Failure</i> , 2021, 43, 1-15.	0.8	25
77	Polycystin-1 regulates ARHGAP35-dependent centrosomal RhoA activation and ROCK signaling. <i>JCI Insight</i> , 2020, 5, .	2.3	25
78	The Role of Phospholipase D in Modulating the MTOR Signaling Pathway in Polycystic Kidney Disease. <i>PLoS ONE</i> , 2013, 8, e73173.	1.1	25
79	Atrial natriuretic peptide release responds to atrial stretch and not to atrial pressure: observations during pericardiocentesis in a young woman. <i>European Heart Journal</i> , 1990, 11, 368-371.	1.0	23
80	Core Outcome Domains for Trials in Autosomal Dominant Polycystic Kidney Disease: An International Delphi Survey. <i>American Journal of Kidney Diseases</i> , 2020, 76, 361-373.	2.1	23
81	Hypersensitivity vasculitis complicating intravenous streptokinase therapy in acute myocardial infarction. <i>International Journal of Cardiology</i> , 1988, 21, 71-73.	0.8	22
82	A Single Amino Acid Residue Constitutes the Third Dimerization Domain Essential for the Assembly and Function of the Tetrameric Polycystin-2 (TRPP2) Channel. <i>Journal of Biological Chemistry</i> , 2011, 286, 18994-19000.	1.6	22
83	Screening for intracranial aneurysms in ADPKD. <i>BMJ: British Medical Journal</i> , 2009, 339, b3763-b3763.	2.4	21
84	Peroxisome Proliferator-Activated Receptor Gamma Agonists in Kidney Disease – Future Promise, Present Fears. <i>Nephron Clinical Practice</i> , 2009, 112, c230-c241.	2.3	21
85	The cAMP Signaling Pathway and Direct Protein Kinase A Phosphorylation Regulate Polycystin-2 (TRPP2) Channel Function. <i>Journal of Biological Chemistry</i> , 2015, 290, 23888-23896.	1.6	21
86	Establishing a Core Outcome Set for Autosomal Dominant Polycystic Kidney Disease: Report of the Standardized Outcomes in Nephrology – Polycystic Kidney Disease (SONG-PKD) Consensus Workshop. <i>American Journal of Kidney Diseases</i> , 2021, 77, 255-263.	2.1	21
87	Polycystin-1 but not polycystin-2 deficiency causes upregulation of the mTOR pathway and can be synergistically targeted with rapamycin and metformin. <i>Pflugers Archiv European Journal of Physiology</i> , 2013, 466, 1591-604.	1.3	20
88	The Sorting Nexin 3 Retromer Pathway Regulates the Cell Surface Localization and Activity of a Wnt-Activated Polycystin Channel Complex. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 2973-2984.	3.0	20
89	Standardised Outcomes in Nephrology – Polycystic Kidney Disease (SONG-PKD): study protocol for establishing a core outcome set in polycystic kidney disease. <i>Trials</i> , 2017, 18, 560.	0.7	20
90	Identifying patient-important outcomes in polycystic kidney disease: An international nominal group technique study. <i>Nephrology</i> , 2019, 24, 1214-1224.	0.7	20

#	ARTICLE	IF	CITATIONS
91	Polycystin-2 expression is increased following experimental ischaemic renal injury. <i>Nephrology Dialysis Transplantation</i> , 2002, 17, 2138-2144.	0.4	18
92	Genetic Testing in the Assessment of Living Related Kidney Donors at Risk of Autosomal Dominant Polycystic Kidney Disease. <i>Transplantation</i> , 2015, 99, 1023-1029.	0.5	18
93	A high throughput zebrafish chemical screen reveals ALK5 and non-canonical androgen signalling as modulators of the <i>pkd2<sup>Δ</sup>/Δ</i> phenotype. <i>Scientific Reports</i> , 2020, 10, 72.	1.6	18
94	Autosomal dominant polycystic kidney disease: recent advances in clinical management. <i>F1000Research</i> , 2016, 5, 2029.	0.8	17
95	Sinus arrest and asystole due to severe lithium intoxication. <i>International Journal of Cardiology</i> , 1991, 30, 364-366.	0.8	16
96	Endothelin and Tubulointerstitial Renal Disease. <i>Seminars in Nephrology</i> , 2015, 35, 197-207.	0.6	16
97	A rapid high-performance semi-automated tool to measure total kidney volume from MRI in autosomal dominant polycystic kidney disease. <i>European Radiology</i> , 2019, 29, 4188-4197.	2.3	16
98	Range and Variability of Outcomes Reported in Randomized Trials Conducted in Patients With Polycystic Kidney Disease: A Systematic Review. <i>American Journal of Kidney Diseases</i> , 2020, 76, 213-223.	2.1	16
99	Tubulointerstitial actions of endothelins in the kidney: roles in health and disease. <i>Nephrology Dialysis Transplantation</i> , 1996, 11, 251-257.	0.4	14
100	Autosomal dominant polycystic kidney disease. <i>Clinical Medicine</i> , 2009, 9, 278-283.	0.8	13
101	The Controversial Role of Fibrosis in Autosomal Dominant Polycystic Kidney Disease. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8936.	1.8	13
102	Endothelin in Polycystic Kidney Disease. <i>Contributions To Nephrology</i> , 2011, 172, 200-209.	1.1	12
103	Primary cilia and renal cysts: does length matter?. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 2661-2663.	0.4	12
104	Tolvaptan slows disease progression in late-stage ADPKD. <i>Nature Reviews Nephrology</i> , 2018, 14, 146-148.	4.1	12
105	Renal monocyte chemoattractant protein-1: an emerging universal biomarker and therapeutic target for kidney diseases?. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 198-203.	0.4	12
106	Building a network of ADPKD reference centres across Europe: the EuroCYST initiative. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, iv26-iv32.	0.4	11
107	Targeting new cellular disease pathways in autosomal dominant polycystic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, 2144-2144.	0.4	11
108	Tuberous Sclerosis Complex (TSC): Expert Recommendations for Provision of Coordinated Care. <i>Frontiers in Neurology</i> , 2019, 10, 1116.	1.1	11



#	ARTICLE	IF	CITATIONS
109	Metformin induces lactate accumulation and accelerates renal cyst progression in <i>Pkd1</i> -deficient mice. <i>Human Molecular Genetics</i> , 2022, 31, 1560-1573.	1.4	11
110	The ERA-EDTA Working Group on inherited kidney disorders. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 67-69.	0.4	10
111	Sudden death due to subarachnoid haemorrhage in an infant with autosomal dominant polycystic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, iv121-iv123.	0.4	10
112	Spurious hypophosphatemia associated with monoclonal paraproteinemia. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2012, 105, 693-696.	0.2	9
113	Making sense of polycystic kidney disease. <i>Lancet, The</i> , 2017, 389, 1780-1782.	6.3	9
114	An <i>Nphp1</i> knockout mouse model targeting exon 2 <sup>Δ</sup> 20 demonstrates characteristic phenotypes of human nephronophthisis. <i>Human Molecular Genetics</i> , 2021, 31, 232-243.	1.4	9
115	Tubular-derived cytokines and human renal disease progression. <i>Nephrology Dialysis Transplantation</i> , 1994, 9, 471-472.	0.4	8
116	Post-translational modifications of the polycystin proteins. <i>Cellular Signalling</i> , 2020, 72, 109644.	1.7	7
117	Thiazolidinediones inhibit MDCK cyst growth through disrupting oriented cell division and apicobasal polarity. <i>American Journal of Physiology - Renal Physiology</i> , 2011, 300, F1375-F1384.	1.3	6
118	TAMEing ADPKD with metformin: safe and effective?. <i>Kidney International</i> , 2021, 100, 513-515.	2.6	6
119	Surprising new roles for endothelins. <i>BMJ: British Medical Journal</i> , 1996, 312, 195-196.	2.4	6
120	Can ketogenic dietary interventions slow disease progression in ADPKD: what we know and what we don't. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 1034-1036.	1.4	6
121	“A sword of Damocles”: patient and caregiver beliefs, attitudes and perspectives on presymptomatic testing for autosomal dominant polycystic kidney disease: a focus group study. <i>BMJ Open</i> , 2020, 10, e038005.	0.8	5
122	Effects of noradrenaline infusion on platelet catecholamine levels and platelet aggregation. <i>Journal of Hypertension</i> , 1989, 7, S166-167.	0.3	4
123	Tubulointerstitial actions of endothelins in the kidney: roles in health and disease. <i>Nephrology Dialysis Transplantation</i> , 0, , .	0.4	4
124	Towards the Integration of Genetic Knowledge into Clinical Practice. <i>Nephron Clinical Practice</i> , 2011, 118, c3-c8.	2.3	4
125	Linear and Nonlinear Estimated GFR Slopes in ADPKD Patients Reaching ESRD. <i>American Journal of Kidney Diseases</i> , 2018, 71, 912-913.	2.1	4
126	New onset diabetes after kidney transplantation in patients with autosomal dominant polycystic kidney disease: systematic review protocol: Figure 1. <i>BMJ Open</i> , 2015, 5, e008440.	0.8	3



#	ARTICLE	IF	CITATIONS
127	Research priorities for autosomal dominant polycystic kidney disease: a UK priority setting partnership. <i>BMJ Open</i> , 2022, 12, e055780.	0.8	3
128	Flank pain has a significant adverse impact on quality of life in ADPKD: the CYSTic-QoL study. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 2063-2071.	1.4	3
129	Intermittent absorption of warfarin caused by an unrecognized pharyngeal pouch.. <i>Postgraduate Medical Journal</i> , 1989, 65, 660-661.	0.9	2
130	A novel dephosphorylation-activated conductance in a mouse renal collecting duct cell line. <i>Experimental Physiology</i> , 2009, 94, 914-927.	0.9	2
131	Drug repurposing in autosomal dominant polycystic kidney disease: back to the future with pioglitazone. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 1715-1718.	1.4	2
132	Individualized everolimus treatment for tuberous sclerosis-related angiomyolipoma promotes treatment adherence and response. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 1160-1168.	1.4	2
133	The Use of Lithium Clearance in Bartter's Syndrome. <i>Nephrology Dialysis Transplantation</i> , 1990, 5, 904-905.	0.4	1
134	Cyst formation in ADPKD: new insights from natural and targeted mutants. <i>Nephrology Dialysis Transplantation</i> , 1999, 14, 544-546.	0.4	1
135	FP064ASSESSING THE LONG TERM OUTCOMES OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD) USING THE ADPKD OUTCOMES MODEL: A UK CASE STUDY. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, iii85-iii86.	0.4	1
136	Backbone assignment and secondary structure of the PLAT domain of human polycystin-1. <i>Biomolecular NMR Assignments</i> , 2015, 9, 369-373.	0.4	1
137	FO026GLOBAL MICRORNA PROFILING IN HUMAN URINARY EXOSOMES REVEALS NEW DISEASE BIOMARKERS AND CELLULAR PATHWAYS FOR AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD). <i>Nephrology Dialysis Transplantation</i> , 2019, 34, .	0.4	1
138	Autosomal dominant polycystic kidney disease. , 2015, , 2627-2633.		1
139	Oncogenous hypophosphataemic osteomalacia: effects on phosphate transport and vitamin D metabolism in cultured human kidney cells. <i>Bone</i> , 1995, 16, 679.	1.4	0
140	An unusual complication of pregnancy. <i>Nephrology Dialysis Transplantation</i> , 1999, 14, 1324-1326.	0.4	0
141	Genetic Renal Abnormalities. <i>Medicine</i> , 2003, 31, 32-35.	0.2	0
142	Homophilic and heterophilic polycystin 1 interactions regulate E-cadherin recruitment and junction assembly in MDCK cells. <i>Journal of Cell Science</i> , 2009, 122, 1702-1702.	1.2	0
143	Structural and Molecular Basis of the Assembly of the TRPP2/PKD1 Complex. <i>Biophysical Journal</i> , 2010, 98, 344a.	0.2	0
144	What's new in Ciliopathies. <i>Medicine</i> , 2011, 39, 119-125.	0.2	0

#	ARTICLE	IF	CITATIONS
145	32 PKD2 mutant zebrafish display excessive developmental angiogenesis. Heart, 2011, 97, e7-e7.	1.2	0
146	RENAL DEVELOPMENT AND CYSTIC DISEASES. Nephrology Dialysis Transplantation, 2014, 29, iii73-iii78.	0.4	0
147	Development Of A Model To Predict Disease Progression In Autosomal Dominant Polycystic Kidney Disease (ADPKD). Value in Health, 2014, 17, A564.	0.1	0
148	SuO042POLYCYSTIN-1 TRAFFICKING IS REGULATED BY CAMP DEPENDENT PHOSPHORYLATION OF THE PLAT DOMAIN. Nephrology Dialysis Transplantation, 2015, 30, iii63-iii63.	0.4	0
149	FP364INCREASED PSYCHOSOCIAL BURDEN AND ADVERSE QUALITY OF LIFE IN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE. Nephrology Dialysis Transplantation, 2015, 30, iii190-iii190.	0.4	0
150	SO052DEVELOPMENT OF A RAPID SEMI-AUTOMATED TOOL TO MEASURE TOTAL KIDNEY VOLUME IN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE. Nephrology Dialysis Transplantation, 2016, 31, i22-i22.	0.4	0
151	SO053SELECTIVE PROSTAGLANDIN E2 RECEPTOR BLOCKADE FOR THE TREATMENT OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE. Nephrology Dialysis Transplantation, 2016, 31, i22-i23.	0.4	0
152	The Cyclic AMP Signaling Pathway and Direct PKA Phosphorylation Regulate Polycystin-2 (TRPP2) Channel Function. Biophysical Journal, 2016, 110, 611a-612a.	0.2	0
153	Development of a rapid semi-automated tool to measure total kidney volume in autosomal dominant polycystic kidney disease. Lancet, The, 2017, 389, S90.	6.3	0
154	TO033VERY EARLY-ONSET AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE DUE TO BI-ALLELIC MUTATIONS IN PKD1 AND PKD2. Nephrology Dialysis Transplantation, 2017, 32, iii94-iii94.	0.4	0
155	SAT-100 "A SWORD OF DAMOCLES" PATIENT AND CAREGIVER BELIEFS, ATTITUDES AND PERSPECTIVES ON GENETIC SCREENING AND TESTING FOR AUTOSOMAL POLYCYSTIC KIDNEY DISEASE - FOCUS GROUP STUDY. Kidney International Reports, 2019, 4, S48.	0.4	0
156	SAT-334 GENETIC TESTING OF FAMILIES WITH VERY EARLY ONSET POLYCYSTIC KIDNEY DISEASE REVEALS THE FUNCTIONAL SIGNIFICANCE OF HYPOMORPHIC VARIANTS. Kidney International Reports, 2019, 4, S148.	0.4	0
157	SaO005CLINICAL PRESENTATION AND PROGNOSIS OF DNAJB11-ASSOCIATED NEPHROPATHY: AN INTERNATIONAL COLLABORATIVE STUDY. Nephrology Dialysis Transplantation, 2019, 34, .	0.4	0
158	SAT-442 Identification of Exosome MicroRNAs as Novel Biomarkers for Rapid Disease Progression in Autosomal Dominant Polycystic Kidney Disease. Kidney International Reports, 2020, 5, S185.	0.4	0
159	SO092REDUCED QUALITY OF LIFE IN ADPKD PATIENTS WITH CKD STAGE 1-3: THE CYSTIC I QUALITY OF LIFE STUDY. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	0
160	MO023FLANK PAIN HAS A MAJOR NEGATIVE IMPACT ON HEALTH-RELATED QUALITY OF LIFE IN ADPKD: THE CYSTIC I STUDY. Nephrology Dialysis Transplantation, 2021, 36, .	0.4	0
161	TRPP2 in Polycystic Kidney Disease. , 2014, , 491-522.		0
162	Genetics and Genomics of Chronic Kidney Disease. , 2014, , 369-392.		0

#	ARTICLE	IF	CITATIONS
163	Autosomal dominant polycystic kidney disease. , 2015, , 2625-2626.		0
164	Imaging of kidney cysts and cystic kidney diseases in children. Consensus paper by an ad hoc committee. Ultraschall in Der Medizin, 2018, 39, .	0.8	0
165	FC029: A Multivariate Model Identifies Genotype, Hypertension and Kidney Length as Independent Baseline Predictors of Disease Progression in a Longitudinal Autosomal Dominant Polycystic Kidney Disease Patient Cohort. Nephrology Dialysis Transplantation, 2022, 37, .	0.4	0
166	MO030: Familial clustering of a rare UMOD variant in undiagnosed hereditary nephropathy suggests the presence of a common ancestral founder mutation. Nephrology Dialysis Transplantation, 2022, 37, .	0.4	0
167	MO015: The Interaction of Gender and Genotype in the Development of Polycystic Liver Disease in ADPKD. Nephrology Dialysis Transplantation, 2022, 37, .	0.4	0